The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease

Thrombosis and Haemostasis

Volumn 112, Issue 6, 2014, Pages 1142-1150

  Neergaard Petersen, Søs ^a,b   Hvas, Anne Mette ^a   Kristensen, Steen D ^a   Grove, Erik L ^a   Larsen, Sanne B ^a   Phoenix, Fladia ^b   Kurdee, Zeyad ^b   Grant, Peter J ^b   Ajjan, Ramzi A ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Coronary artery disease; Fibrin clot; Fibrinolysis; Inflammation; Type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; AUTACOID; C REACTIVE PROTEIN; C3 PROTEIN, HUMAN; COMPLEMENT COMPONENT C3; FIBRIN; FIBRINOGEN;

AGED; BLOOD; BLOOD CLOTTING TEST; CASE CONTROL STUDY; COMPLICATION; CONFOCAL MICROSCOPY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG EFFECTS; FEMALE; FIBRINOLYSIS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PHOTOMETRY; REGISTER; RISK FACTOR; SCANNING ELECTRON MICROSCOPY; SEX DIFFERENCE; TIME;

AGED; ASPIRIN; BLOOD COAGULATION TESTS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COMPLEMENT C3; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FIBRIN; FIBRINOGEN; FIBRINOLYSIS; HUMANS; INFLAMMATION MEDIATORS; MALE; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PLATELET AGGREGATION INHIBITORS; REGISTRIES; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 84914109016     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-05-0468     Document Type: Article

References (45)

1. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–2128.
2. Grant PJ. Inflammatory, atherothrombotic aspects of type 2 diabetes. Curr Med Res Opin 2005; 21 (Suppl 1): S5–12.
3. Fox CS, Coady S, Sorlie PD et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007; 115: 1544–1550.
4. Cubbon RM, Wheatcroft SB, Grant PJ et al. Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur Heart J 2007; 28: 540–545.
5. Norhammar A, Lindback J, Ryden L et al. Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart 2007; 93: 1577–1583.
6. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. Br Med J 2006; 332: 73–78.
7. Ajjan RA, Standeven KF, Khanbhai M et al. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol 2009; 29: 712–717.
8. He S, Bark N, Wang H et al. Effects of acetylsalicylic acid on increase of fibrin network porosity and the consequent upregulation of fibrinolysis. J Cardiovasc Pharmacol 2009; 53: 24–29.
9. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860.
10. Mortensen SB, Larsen SB, Grove EL et al. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res 2010; 126: 318–322.
11. Larsen SB, Neergaard-Petersen S, Grove EL et al. Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction. Thromb Haemost 2012; 108: 140–147.
12. Neergaard-Petersen S, Ajjan R, Hvas AM et al. Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure. PLoS One 2013; 8: e71150.
13. Tehrani S, Antovic A, Mobarrez F et al. High-dose aspirin is required to influence plasma fibrin network structure in patients with type 1 diabetes. Diabetes Care 2012; 35: 404–408.
14. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008; 51: 385–390.
15. Ajjan R, Grant PJ. Coagulation and atherothrombotic disease. Atherosclerosis 2006; 186: 240–259.
16. Collet JP, Allali Y, Lesty C et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567–2573.
17. Undas A, Kolarz M, Kopec G et al. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality. Nephrol Dial Transplant 2008; 23: 2010–2015.
18. Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005; 48: 1198–1206.
19. Fatah K, Silveira A, Tornvall P et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535–540.
20. Dunn EJ, Philippou H, Ariens RA et al. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49: 1071–1080.
21. Bochenek M, Zalewski J, Sadowski J et al. Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease. J Thromb Thrombolysis 2013; 35: 264–270.
22. Alzahrani SH, Hess K, Price JF et al. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. J Clin Endocrinol Metab 2012; 97: E2282-E2287.
23. Ajjan RA, Gamlen T, Standeven KF et al. Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. Blood 2013; 122: 134–142.
24. Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res 2010; 7: 260–273.
25. Sjoland JA, Sidelmann JJ, Brabrand M et al. Fibrin clot structure in patients with end-stage renal disease. Thromb Haemost 2007; 98: 339–345.
26. Undas A, Plicner D, Stepien E et al. Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine. J Thromb Haemost 2007; 5: 1988–1990.
27. Howes JM, Richardson VR, Smith KA et al. Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diab Vasc Dis Res 2012; 9: 216–225.
28. Hess K, Alzahrani SH, Mathai M et al. A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia 2012; 55: 1103–1113.
29. Carter AM, Cymbalista CM, Spector TD et al. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2007; 27: 2783–2789.
30. Al-Barjas HS, Ariens R, Grant P et al. Raised plasma fibrinogen concentration in patients with abdominal aortic aneurysm. Angiology 2006; 57: 607–614.
31. Human Complement C3 ELISA Quantification Kit, Manual, Catolog number: 40–288-20073F. GenWay Biotech, Inc, San Diego, CA, USA 2012.
32. Ajjan R, Lim BC, Standeven KF et al. Common variation in the C-terminal region of the fibrinogen beta-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood 2008; 111: 643–650.
33. Takebe M, Soe G, Kohno I et al. Calcium ion-dependent monoclonal antibody against human fibrinogen: preparation, characterization, and application to fibrinogen purification. Thromb Haemost 1995; 73: 662–667.
34. James S, Angiolillo DJ, Cornel JH et al. Ticagrelor vs clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010; 31: 3006–3016.
35. Patrono C, Rocca B. Drug insight: aspirin resistance--fact or fashion? Nat Clin Pract Cardiovasc Med 2007; 4: 42–50.
36. Pieters M, Covic N, Loots dT et al. The effect of glycaemic control on fibrin network structure of type 2 diabetic subjects. Thromb Haemost 2006; 96: 623–629.
37. Pieters M, Covic N, van der Westhuizen FH et al. Glycaemic control improves fibrin network characteristics in type 2 diabetes – a purified fibrinogen model. Thromb Haemost 2008; 99: 691–700.
38. Mills JD, Ariens RA, Mansfield MW et al. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938–1942.
39. Neergaard-Petersen S, Hvas AM, Ajjan R et al. Platelet count, platelet turnover and fibrin clot structure in patients with coronary artery disease. Thromb Res 2014; 133: 1161–1163.
40. Hethershaw EL, Cilia La Corte AL, Duval C et al. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J Thromb Haemost 2014; 12: 197–205.
41. Lutjens A, Jonkhoff-Slok TW, Sandkuijl C et al. Polymerisation and crosslinking of fibrin monomers in diabetes mellitus. Diabetologia 1988; 31: 825–830.
42. Duval C, Allan P, Connell SD et al. Roles of fibrin alpha- and gamma-chain specific cross-linking by FXIIIa in fibrin structure and function. Thromb Haemost 2014; 111: 842–850.
43. Vaccarino V, Badimon L, Corti R et al. Presentation, management, and outcomes of ischaemic heart disease in women. Nat Rev Cardiol 2013; 10: 508–518.
44. Dey S, Flather MD, Devlin G et al. Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart 2009; 95: 20–26.
45. Berger JS, Elliott L, Gallup D et al. Sex differences in mortality following acute coronary syndromes. J Am Med Assoc 2009; 302: 874–882.